TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23992543

Group type: EXPERIMENTAL
Intervention: T1DM subjects (n=25)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-diabetic controls (n=16)
Number of subjects: 25
Study: 22270216

Group type: EXPERIMENTAL
Intervention: Prednisone (steroid group) for 15 days starting with 100 mg at surgery, tapered to 12.5 mg.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo (control group) administered in a comparable manner to the steroid group.
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Prednisone (steroid group)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 220
Study: 20669035

Group type: EXPERIMENTAL
Intervention: Self-help workbook intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: No-workbook control
Number of subjects: 40
Study: 17207145

Group type: EXPERIMENTAL
Intervention: Participation in the trial (all children)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Participation in the trial (some children)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Participation in the trial (none)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Factors associated with all children participating
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Factors associated with some children participating
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Future use of the Vi vaccine
Number of subjects: 461
Study: 16444992

Group type: EXPERIMENTAL
Intervention: Sentinel lymphoscintigrams in patients undergoing excisional biopsy
Number of subjects: 159

Group type: COMPARATOR
Intervention: Sentinel lymphoscintigrams in patients without excisional biopsy
Number of subjects: 159
Study: 12873566

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (osmolality 1030 mOsm/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochloric acid (pH 1 and 2.5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acidified hypertonic saline (pH 1 and 2.5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochloric acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acidified hypertonic saline
Number of subjects: 0
Study: 10554747

Group type: EXPERIMENTAL
Intervention: Prilocaine plus lidocaine cream (Group A)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Lidocaine spray (Group B)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No anesthesia (Control Group C)
Number of subjects: 180
Study: 8725992

Group type: EXPERIMENTAL
Intervention: E. coli isolates from hospitalized diabetic patients
Number of subjects: 300

Group type: COMPARATOR
Intervention: E. coli isolates from non-hospitalized diabetic patients
Number of subjects: 300

Group type: COMPARATOR
Intervention: E. coli isolates from non-diabetic patients
Number of subjects: 300
Study: 1659601

Group type: EXPERIMENTAL
Intervention: Immunoblot assay using recombinant-baculovirus-expressed glycoprotein G (gG1 or gG2)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Immunodot assay based on gG immunopurified from HSV-1 and HSV-2 infected cells
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Reproducibility of the immunoblot assay
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Results from two laboratories
Number of subjects: 110
Study: 7032852

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aerosol (TAA)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 96
Study: 30679183

Group type: EXPERIMENTAL
Intervention: Allogeneic ASC sheets
Number of subjects: 59

Group type: COMPARATOR
Intervention: Polyurethane film
Number of subjects: 59
Study: 30121091

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation with locked plating technology
Number of subjects: 160

Group type: COMPARATOR
Intervention: Non-operative management
Number of subjects: 160
Study: 27884853

Group type: EXPERIMENTAL
Intervention: Gyejibongneyong-hwan (GBH) administered three times per day for two menstrual periods (8 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo administered three times per day for two menstrual periods (8 weeks)
Number of subjects: 38
Study: 25086653

Group type: EXPERIMENTAL
Intervention: Cholestyramine (8g) for 11 days
Number of subjects: 67
Study: 22172638

Group type: EXPERIMENTAL
Intervention: Chronic psychosocial stressors
Number of subjects: 48
Study: 19466245

Group type: EXPERIMENTAL
Intervention: 3D reformations using shaded surface display (SSD)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 3D reformations using maximum intensity projection (MIP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Multiplanar reformation (MPR)
Number of subjects: 22
Study: 17882046

Group type: EXPERIMENTAL
Intervention: 80, 100, and 120 kVp with 100, 150, and 200 mA (experiment 1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 140, 180, and 220 mA with 100 and 120 kVp (experiment 2)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Randomly used mAs between 60 and 220 with 100 and 120 kVp (experiment 3)
Number of subjects: 13
Study: 15908760

Group type: EXPERIMENTAL
Intervention: Cream preparations containing marigold and rosemary extracts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with undyed marigold and faradiol ester-enriched extracts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with dyed and undyed rosemary extracts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential treatment (postirritation) once a day for 5 days
Number of subjects: 0
Study: 11994110

Group type: EXPERIMENTAL
Intervention: Barrier Endosheath system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immersion in Cidex disinfectant
Number of subjects: 0
Study: 9667295

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Head-up position (after norepinephrine or phenylephrine infusion)
Number of subjects: 40
Study: 7660342

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms aqueous nasal spray administered twice daily for two weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 24
Study: 2636858

Group type: EXPERIMENTAL
Intervention: Coffee
Number of subjects: 13

Group type: COMPARATOR
Intervention: Herbal Tea (Control)
Number of subjects: 13
Study: 996687

Group type: EXPERIMENTAL
Intervention: Oral oxamniquine at a total dose of 60 mg/kg (given in 4 equal doses morning and evening over 2 days, after food)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower doses or shorter schedules of treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral oxamniquine
Number of subjects: 0
Study: 31990972

Group type: EXPERIMENTAL
Intervention: Decaffeinated energy drink
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 223
Study: 29742935

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 64
Study: 27754927

Group type: EXPERIMENTAL
Intervention: BMI trajectories leading to obesity
Number of subjects: 69873

Group type: EXPERIMENTAL
Intervention: BMI at age 20 years, 50 years, and baseline questionnaire
Number of subjects: 69873

Group type: COMPARATOR
Intervention: BMI trajectories
Number of subjects: 69873
Study: 26016699

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/daily for 1 week and then for the first 2 days of every month for the following 3 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 23937748

Group type: EXPERIMENTAL
Intervention: Minimally invasive plating osteosynthesis
Number of subjects: 47

Group type: COMPARATOR
Intervention: Intramedullary nailing (IMN)
Number of subjects: 47
Study: 21941878

Group type: EXPERIMENTAL
Intervention: Presence of captions
Number of subjects: 62

Group type: COMPARATOR
Intervention: No captions (Control)
Number of subjects: 62
Study: 19253239

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with peripheral iridectomy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Phaco-trabeculectomy with peripheral iridectomy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Trabeculectomy without peripheral iridectomy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Phaco-trabeculectomy without peripheral iridectomy
Number of subjects: 47
Study: 16393306

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg administered i.v. over 20 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15233978

Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril combination therapy (5 mg and 10 mg with 40 mg benazepril)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benazepril hydrochloride (40 mg) alone
Number of subjects: 0
Study: 11316720

Group type: EXPERIMENTAL
Intervention: Oral famciclovir 500 mg three times daily
Number of subjects: 454

Group type: COMPARATOR
Intervention: Oral aciclovir 800 mg five times daily
Number of subjects: 454
Study: 9159566

Group type: COMPARATOR
Intervention: Dopamine 0 microg kg(‐1) min(‐1) (placebo)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dopamine 1 microg kg(‐1) min(‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dopamine 2 microg kg(‐1) min(‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dopamine 3 microg kg(‐1) min(‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dopamine 5 microg kg(‐1) min(‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dopamine 7.5 microg kg(‐1) min(‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dopamine 10 microg kg(‐1) min(‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dopamine 12.5 microg kg(‐1) min(‐1)
Number of subjects: 8
Study: 7967191

Group type: EXPERIMENTAL
Intervention: 123I-IMP SPECT
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: EEG
Number of subjects: 19
Study: 3555587

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg + hydrochlorothiazide (HCTZ) 25 mg once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Captopril 25 mg twice daily
Number of subjects: 12
Study: 30917183

Group type: EXPERIMENTAL
Intervention: Requests from affluent constituents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Requests from poor constituents
Number of subjects: 0
Study: 28662731

Group type: EXPERIMENTAL
Intervention: Protein-enriched foods and drinks (12-week intervention)
Number of subjects: 75
Study: 26215901

Group type: EXPERIMENTAL
Intervention: Real-time feedback (inertial sensor)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Traditional method (no feedback)
Number of subjects: 61
Study: 23434165

Group type: EXPERIMENTAL
Intervention: Food deprivation for up to 66 hours
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sleep deprivation for up to 50 hours
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nondeprived instructors
Number of subjects: 45
Study: 21973229

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 127
Study: 18058818

Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg/day for 10-14 days before surgery
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no NSAID)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 53
Study: 16937589

Group type: EXPERIMENTAL
Intervention: TB + Flossing (TB + Fl)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Tongue brushing and toothbrushing (TB)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: TB + Fl
Number of subjects: 102

Group type: COMPARATOR
Intervention: TB
Number of subjects: 102
Study: 15319157

Group type: EXPERIMENTAL
Intervention: diclofenac‐Na 0.1% Emulgel gel
Number of subjects: 172

Group type: COMPARATOR
Intervention: vehicle Emulgel gel
Number of subjects: 172
Study: 11149011

Group type: EXPERIMENTAL
Intervention: Weekly i.v. bolus injection of 5‐fluorouracil 400 mg/m2 plus leucovorin 20 mg/m2
Number of subjects: 96

Group type: COMPARATOR
Intervention: Monthly i.v. bolus injection of 5‐fluorouracil 425 mg/m2 plus leucovorin 20 mg/m2 for 5 consecutive days every 4 or 5 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Monthly arm
Number of subjects: 96
Study: 9076817

Group type: EXPERIMENTAL
Intervention: Miconazole gel (25 mg, four times daily)
Number of subjects: 227
Study: 8407753

Group type: EXPERIMENTAL
Intervention: Combined methylphenidate and desipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desipramine alone
Number of subjects: 0
Study: 3948857

Group type: EXPERIMENTAL
Intervention: WIEXP (water immersion with blood volume expansion by intravenous infusion of 2.0 L of isotonic saline for 2 hours)
Number of subjects: 8

Group type: COMPARATOR
Intervention: WIHEM (water immersion with blood volume reduction by loss of 0.5 L of blood during 30 minutes)
Number of subjects: 8
Study: 29723020

Group type: EXPERIMENTAL
Intervention: Baseline violence
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Baseline alcohol misuse
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Increases in PTSD symptoms between Waves 1 and 2
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Decreases in social support between Waves 1 and 2
Number of subjects: 1090
Study: 27630503

Group type: EXPERIMENTAL
Intervention: Demineralized freeze-dried bone allograft (DFDBA) combined with platelet-rich fibrin (PRF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 36
Study: 25265927

Group type: EXPERIMENTAL
Intervention: DECT mode, 0.5 ml per kg of patient weight CM at injection rate=(weight × 0.5 ml/kg)/(4+scan time)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single‐energy CT 70 ml CM at injection rate of 5 ml/s
Number of subjects: 60
Study: 21900307

Group type: EXPERIMENTAL
Intervention: Questionnaire using the word 'placebo'
Number of subjects: 190

Group type: COMPARATOR
Intervention: Questionnaire using the term 'nonspecific methods of treatment'
Number of subjects: 190
Study: 19557486

Group type: EXPERIMENTAL
Intervention: Fenestrated outflow cannula
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional cannulae
Number of subjects: 28
Study: 17288679

Group type: EXPERIMENTAL
Intervention: Losartan-based therapy
Number of subjects: 9193

Group type: COMPARATOR
Intervention: Atenolol-based therapy
Number of subjects: 9193

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg plus hydrochlorothiazide 12.5 mg
Number of subjects: 9193

Group type: COMPARATOR
Intervention: Atenolol 100 mg plus hydrochlorothiazide 12.5 mg
Number of subjects: 9193
Study: 16053996

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (low-dose angiotensin receptor blocker) for 2 years
Number of subjects: 809

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 809
Study: 11876701

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Omeprazole (40 mg)
Number of subjects: 230
Study: 11030815

Group type: EXPERIMENTAL
Intervention: Postoperative application of mitomycin (group 1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intraoperative application of mitomycin (group 2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No mitomycin application (group 3)
Number of subjects: 22
Study: 8674397

Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg four times a day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1456569

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Furosemide (80 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 7
Study: 3881327

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid 750 mg daily
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid 375 mg daily
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 30580675

Group type: EXPERIMENTAL
Intervention: Intimacy Enhancement (IE) intervention
Number of subjects: 29

Group type: COMPARATOR
Intervention: Educational control condition
Number of subjects: 29
Study: 29744900

Group type: EXPERIMENTAL
Intervention: Fluconazole (loading dose 25 mg kg‐1; maintenance dose 12 mg kg‐1 day‐1 for infants <30 weeks or 20 mg kg‐1 day‐1 for infants ≥30 weeks' corrected gestational age)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Micafungin (loading dose 15 mg kg‐1 day‐1; maintenance dose 10 mg kg‐1 day‐1)
Number of subjects: 36
Study: 27098825

Group type: EXPERIMENTAL
Intervention: Face-to-face individual counselling plus telephone follow-up counselling (FCF group)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Face-to-face individual counselling (FC group)
Number of subjects: 457
Study: 25449714

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 464
Study: 23130467

Group type: EXPERIMENTAL
Intervention: Split drug regimen (two times a day)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Once daily regimen
Number of subjects: 122
Study: 20102935

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 10001

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 10001
Study: 18840838

Group type: EXPERIMENTAL
Intervention: 2-point ultrasonography
Number of subjects: 2098

Group type: COMPARATOR
Intervention: Whole-leg ultrasonography
Number of subjects: 2098
Study: 16278523

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 22576

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil
Number of subjects: 22576

Group type: EXPERIMENTAL
Intervention: Combination therapy (verapamil/trandolapril or atenolol/hydrochlorothiazide)
Number of subjects: 22576

Group type: EXPERIMENTAL
Intervention: Triple therapy (verapamil/trandolapril/hydrochlorothiazide or atenolol/hydrochlorothiazide/trandolapril)
Number of subjects: 22576

Group type: COMPARATOR
Intervention: Monotherapy (verapamil or atenolol)
Number of subjects: 22576
Study: 12443949

Group type: EXPERIMENTAL
Intervention: Subjects with knee pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subjects without knee pain
Number of subjects: 0
Study: 10707135

Group type: EXPERIMENTAL
Intervention: 12 mg anthocyanosides
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 24 mg anthocyanosides
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8560999

Group type: EXPERIMENTAL
Intervention: 6 mg estradiol valerate
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 15 mg norethisterone acetate
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30146446

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 157

Group type: COMPARATOR
Intervention: Normal saline solution (0.9% sodium chloride)
Number of subjects: 157
Study: 27911117

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intense Pulsed Light (IPL)
Number of subjects: 70
Study: 25576068

Group type: EXPERIMENTAL
Intervention: Automated measurement of QT and RR during continuous 24-h electrocardiogram recordings
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Manual measurement on 10-s electrocardiograms
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Automated method
Number of subjects: 49

Group type: COMPARATOR
Intervention: Manual method
Number of subjects: 49
Study: 23810097

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21795660

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study: 18581513

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 40 mg/kg intravenously
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 15942580

Group type: EXPERIMENTAL
Intervention: Allon thermoregulation system (AT group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine thermal care (RTC group)
Number of subjects: 90
Study: 12861460

Group type: EXPERIMENTAL
Intervention: Communication skills training program
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (no training program)
Number of subjects: 193
Study: 10802158

Group type: EXPERIMENTAL
Intervention: High monounsaturated fat diet
Number of subjects: 23
Study: 8806289

Group type: EXPERIMENTAL
Intervention: Postoperative radical radiotherapy (50 Gy to breast with boost to the tumour bed)
Number of subjects: 585

Group type: COMPARATOR
Intervention: No further local treatment
Number of subjects: 585
Study: 1503329

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 95)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Usual care group (n = 92)
Number of subjects: 187
Study: 6427416

Group type: EXPERIMENTAL
Intervention: FAM combination (5‐fluorouracil, doxorubicin, and mitomycin C) - simultaneous administration
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: FAM combination (5‐fluorouracil, doxorubicin, and mitomycin C) - sequential administration
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Higher degrees of hematologic toxicity
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Patients treated by community oncologists
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Prior exposure to 5‐fluorouracil
Number of subjects: 239
Study: 30827300

Group type: EXPERIMENTAL
Intervention: Oral massage method with non-nutritive sucking, stimulating swallowing function, and SandraFucile, once a day for 14 consecutive days.
Number of subjects: 151

Group type: COMPARATOR
Intervention: Routine treatment of preterm infants without oral intervention.
Number of subjects: 151
Study: 29086614

Group type: EXPERIMENTAL
Intervention: Cannabidiol (600 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 26460632

Group type: EXPERIMENTAL
Intervention: HYPO (FiO2 ≈ 0.155)
Number of subjects: 11

Group type: COMPARATOR
Intervention: NORM
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: N + H analysis
Number of subjects: 11